Contact email address:
[email protected]<mailto:[email protected]?Subject=Regarding%20the%20job%20listed%20on%20the%20PharmPK%20website>
MedImmune is looking to expand its predictive science group and is recruiting a
Clinical Pharmacokineticist in its Cambridge UK facility.
Reporting to David Fairman within Balaji Agoram's Clinical pharmacology and
DMPK department the Clinical Pharmacokineticist will be responsible for all
aspects of PK/PD-related support for bio therapeutic products.
The Clinical Pharmacokineticist functions as the Global Clinical Pharmacology
and DMPK project leader and team representative for biotherapeutic projects at
all stages of research and development - from discovery through to BLA.
The scientist will be responsible for all aspects of PK/PD-related support for
bio therapeutic products, including design of preclinical and clinical studies,
modeling and simulation analysis, trial simulation, and reporting (including
GLP data) and communication of data in regulatory documents and meetings.
The successful candidate's previous experience will include:
Strong PK/PD experience in the execution and application of modeling and
simulation is essential. Preferably within an industrial setting but a highly
relevant academic lab will be considered. Demonstrate a strong understanding of
the drug development process. Evidence of leading study designs in
collaboration with clinical or preclinical colleagues would be a significant
advantage. Modeling and simulation experience including utilization of packages
such as NONMEM, Berkeley Madonna, S-plus and Matlab. Demonstrable team working
skills with a track record of delivery and communication of high quality
modelling output.
Education: Your experience will be built on a BSc or equivalent as minimum with
MSc or PhD in a relevant field preferred
Please see the link for full description and application details.
External website
http://www.candidatecare.com/srccsh/RTI.home?r=2000018146110&d=medimmune.candidatecare.com
To the extent this electronic communication or any of its attachments contain
information that is not in the public domain, such information is considered by
MedImmune to be confidential and proprietary. This communication is expected to
be read and/or used only by the individual(s) for whom it is intended. If you
have received this electronic communication in error, please reply to the
sender advising of the error in transmission and delete the original message
and any accompanying documents from your system immediately, without copying,
reviewing or otherwise using them for any purpose. Thank you for your
cooperation.